openPR Logo
Press release

Non-Alcoholic Steatohepatitis (NASH) Market Report 2018: Segmentation by Drug (Vitamin E & Pioglitazone, Ocaliva, Elafibranor, Selonsertib & Cenicriviroc, Others) by Sales Channel (Hospital Pharmacy, Online Provider, Retail Pharmacy, Others)

07-09-2018 06:50 PM CET | Health & Medicine

Press release from: Non-Alcoholic Steatohepatitis (NASH) Market Report 2018

Non-Alcoholic Steatohepatitis (NASH) Market

Non-Alcoholic Steatohepatitis (NASH) Market

Global Non-Alcoholic Steatohepatitis (NASH) market research report provides company profile for Allergan plc. (Tobira Therapeutics), Cadila Healthcare Limited, Conatus Pharmaceuticals Inc., Galmed Pharmaceuticals Ltd, Gemphire Therapeutics Inc., Genfit SA, Gilead Sciences, Inc., Intercept Pharmaceuticals, Inc., Novartis International AG, Shire Plc. and Others.

This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in terms of volume, revenue, YOY growth rate, and CAGR for the year 2018 to 2025, etc. The report also provides detailed segmentation on the basis of product type, application, end user and regional segmentation. The regional segment is further bifurcated on country level.

Non-alcoholic steatohepatitis (NASH) market is projected to exhibit double digit growth during the forecast period majorly due to growth in demand for ideal NASH therapeutics, surge in the prevalence of NASH, and expected launch of pipeline drugs during the forecast period. In addition, surge in prevalence of diabetes & obesity and improvement in awareness of NASH in developing region is projected to supplement the market growth during the forecast period. However, poor diagnosis of the disease and lack of ideal diagnostic techniques are projected to limit the market growth.

Request for Free sample copy of ready Report @

Report Coverage:
Top Manufactures/vendors of Non-Alcoholic Steatohepatitis (NASH) market:
Gemphire Therapeutics Inc.
Genfit SA, Gilead Sciences, Inc.
Intercept Pharmaceuticals, Inc.
Novartis International AG
Shire Plc.
Allergan plc. (Tobira Therapeutics)
Cadila Healthcare Limited
Conatus Pharmaceuticals Inc.
Galmed Pharmaceuticals Ltd
Others (Note: We can profile additional players without any additional charges)

Non-Alcoholic Steatohepatitis (NASH) Drug Type:
Vitamin E & Pioglitazone
Selonsertib & Cenicriviroc

Application of Sales Channel:
Hospital Pharmacy
Online Provider
Retail Pharmacy

Regions covered in Non-Alcoholic Steatohepatitis (NASH) Market Research Report:
North America (USA, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Others)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Others)
South America (Brazil, Argentina, Columbia and Others)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa and Others)
(Note: We can provide country or region specific report on request; please contact us for your specific requirement)

The Global Non-Alcoholic Steatohepatitis (NASH) Market analysis report covers detailed value chain analysis of Global Non-Alcoholic Steatohepatitis (NASH) Market. The value chain analysis helps to analyze major upstream raw materials, major equipment’s, manufacturing process, downstream customer analysis and major distributor analysis.
The report also covers in-depth description, competitive scenario, wide product portfolio of prime players active in this market and business strategies adopted by competitors along with their SWOT analysis. The report also provides Porter analysis, PESTEL analysis and market attractiveness which helps to better understand the market scenario on macro and micro level. Side by side, it also explicitly provides information about mergers, acquisitions, joint ventures, and all the other important activities occurred in the market during current and past few years. The Global Non-Alcoholic Steatohepatitis (NASH) Market report explores manufacturer’s competitive scenario and provides market share for all major players of this market based on production capacity, sales, revenue, geographical presence and other major factors. The report also covers import/export data across all major regions covered in this report. Moreover, we can exclusively provide information about import/export data across any particular country as per requirement.

How helpful this report will be?
• Non-Alcoholic Steatohepatitis (NASH) Market share (regional, product, application, end-user) both in terms of volume and revenue along with CAGR from 2018 to 2025
• Key parameters which are driving this market and restraining its growth
• What all challenges manufacturers will face as well as new opportunities and threats faced by them

Enquire before Buying @

Table of Content:
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.3.1. List of key players profiled in the report
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models........................Continue (

What does Report Include?
Historic Data: What was the Non-Alcoholic Steatohepatitis (NASH) Market data (Size, competition, company share, YoY growth rate, etc.) from 2013 to 2018.
Current Market Status: A comprehensive analysis of current market Size, trends, growth drivers, industry pitfalls, challenges and opportunities for players.
Market Forecast: Report will comment and provide details about market growth and forecast till year 2025.
Customization: We can provide following things 1) On request more company profiles (competitors) 2) Data about particular country or region 3) We will incorporate the same with no additional cost (Post conducting feasibility).

Contact Us
Jason Smith,
Sales Manager, Global Business Development,
Contact us: +1-888-220-3424
Address: 20 N State Street, Chicago, Illinois, 60602 United States

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Non-Alcoholic Steatohepatitis (NASH) Market Report 2018: Segmentation by Drug (Vitamin E & Pioglitazone, Ocaliva, Elafibranor, Selonsertib & Cenicriviroc, Others) by Sales Channel (Hospital Pharmacy, Online Provider, Retail Pharmacy, Others) here

News-ID: 1116542 • Views:

More Releases for NASH

NASH Market Insight and Landscape report
Report Snapshot: NASH is one of the furthermost causes of liver disease worldwide and will probably emerge as the leading cause of end-stage liver disease in the coming years, with the disease affecting both adults and children. The epidemiology and demographic characteristics of NASH vary across different country level. Furthermore, individuals with NAFLD have a high frequency of metabolic comorbidities and could place a growing strain on health-care systems from their
IQ4I Research published “Non-alcoholic steatohepataitis (NASH) Pipeline Analys …
“Non-alcoholic steatohepataitis (NASH) Pipeline Analysis” gives comprehensive insights on the various drugs being developed for the treatment of NASH. The report covers all the drugs that are in various phases of development (Discovery, Preclinical & Clinical). The pipeline focuses on novel pharmacologic drugs & regenerative medicines covering small molecules, antibodies, stem cell therapies, recombinant proteins and RNA-based therapeutics, but excludes symptom relief drugs, generic combinations and supplemental drugs. The report
Growing Prevalence of NASH to Increase Adoption of Therapeutics
"The Report OpportunityAnalyzer: NASH - Opportunity Analysis and Forecasts to 2026 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. -" has itemized the addition of a new market research report to its report repository. The research publication is titled, “Opportunity Analyzer: NASH - Opportunity Analysis and Forecasts to 2026.” The statistical surveying study is a watchful inspection of the general market
OpportunityAnalyzer: NASH - Opportunity Analysis and Forecasts to 2026
First described in 1980, nonalcoholic steatohepatitis (NASH) (ICD-10-CM = K75.81) is a condition that develops as a subgroup of nonalcoholic fatty liver disease (NAFLD) when excessive fat buildup is accompanied by liver cell injury and inflammation. NAFLD is defined by excessive fat accumulation in the form of triglycerides (steatosis) in the liver. Progression of this condition to NASH dramatically increases the risk of cirrhosis, liver failure, and hepatocellular carcinoma, and
04-07-2017 | Arts & Culture
Memphia PR
Nash releases debut EP 'She Don't Know'
London-based singer/songwriter Nash has released his debut EP She Don’t Know. Recorded at the legendary RAK Studios, She Don’t Know has the feel of 60s rock but with a modern twist, leaving the listener hooked throughout and wanting to come back for another listen. She Don’t Know’s leading single CK is an infectious number which is sure to be a hit for 2017. Listening to the Beatles and Jack White growing
Nash Technologies at GITEX/GULFCOMMS 2010
Harvey Nash subsidiary presents expert services to telecom operators in the Middle East, Africa and South Asia region Nürnberg/Germany, 10th September 2010 – For the first time Nash Technologies will be present at GITEX/GULFCOMMS, the largest international trade event for mobile, fixed, IP and satellite communications for the Middle East, Africa and South Asia region, in Dubai from 17th to 21st October 2010 offering its telecom expert services. Nash Technologies will